Dr. Banerjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Avenue East
Mail Stop LG-650
Seattle, WA 98109- Is this information wrong?
Summary
- Dr. Banerjee, MD, FACP, is an Assistant Professor at the University of Washington (Seattle, WA) as well as at the Fred Hutchinson Cancer Center. His clinical interests are in multiple myeloma and CAR-T therapy. His research interests are in toxicity management, digital health, and improving the patient experience in multiple myeloma.
Education & Training
University of California San FranciscoAdvanced Fellowship, BMT/CAR-T Therapy, 2021 - 2022
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2018 - 2021
University of Pennsylvania Health SystemChief Residency, Internal Medicine, 2017 - 2018- University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2017
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2014 - 2015
The Warren Alpert Medical School of Brown UniversityClass of 2014, MD, AOA Inductee
Certifications & Licensure
CA State Medical License 2018 - 2026
WA State Medical License 2022 - 2025
PA State Medical License 2014 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Winner, Department of Medicine ‘Shelter-in-Poetry’ Competition University of California San Francisco, 2020
- Samaha Award for resident scholarship Penn Medicine, 2017
- Penn Pearls Award Recipient Perelman School of Medicine, University of Pennsylvania, 2017
- Join now to see all
Clinical Trials
- Digital Life Coaching for Myeloma Patients Undergoing Transplantation Start of enrollment: 2020 May 20
- Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation Start of enrollment: 2020 Dec 29
- Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab Start of enrollment: 2022 Jun 17
- Join now to see all
Publications & Presentations
PubMed
- Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.Adeel M Khan, Georgia McCaughan, Xiaoliang Wang, James Roose, Larry D Anderson Jr, Fieke W Hoff, Rahul Banerjee, Bo Wang, Andrew J Cowan, S Vincent Rajkumar, Gurbakhas...> ;Blood Cancer Journal. 2024 Mar 22
- Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma.Reyes, K., Huang, C., Martin, T., Wong, S., Wolf, J., Shah, N., Chung, A., Liu, Y., Banerjee, R., Arora, S., Chari, A.> ;Blood Advances. 2024 Mar 1
- Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
- Join now to see all
Journal Articles
- IlliteracyBanerjee R, The Pharos of Alpha Omega Alpha Honor Medical Society, 2/21/2017
Books/Book Chapters
Press Mentions
CAR-T therapies and cancer risk: No easy answers for the FDAJanuary 26th, 2024
FDA Requests Class-Wide Boxed Warning for CAR T-Cell Agents Regarding Secondary T-Cell Malignancy RiskJanuary 25th, 2024
FDA Calls for Boxed Warnings on CAR-T Therapies Regarding Secondary Cancer RisksJanuary 23rd, 2024- Join now to see all
Grant Support
- Young Investigator AwardASCO Conquer Cancer Foundation2020–2022
Professional Memberships
- Member
- Member
- Member
- Member
- American Society for Transplantation and Cellular TherapyMember
- Member
Other Languages
- Hindi, Bengali
Hospital Affiliations
Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
